Abstract:Smallpox, a disease caused by the variola virus, is one of the most dangerous diseases and had killed numerous people before it was eradicated in 1980. However, smallpox has emerged as the most threatening bio-terrorism agent; as the first- and second-generation smallpox vaccines have been controversial and have caused severe adverse reactions, new demands for safe smallpox vaccines have been raised and some attenuated smallpox vaccines have been developed. We have developed a cell culture-based highly attenuated third-generation smallpox vaccine candidate KVAC103 strain by 103 serial passages of the Lancy-Vaxina strain derived from the Lister in Vero cells. Several clones were selected, taking into consideration their shape, size, and growth rate in mammalian cells. The clones were then inoculated intracerebrally in suckling mice to test for neurovirulence by observing survival. Protective immune responses in adult mice were examined by measuring the levels of neutralization antibodies and IFN-γ expression. Among several clones, clone 7 was considered the best alternative candidate because there was no mortality in suckling mice against a lethal challenge. In addition, enhanced neutralizing antibodies and T-cell mediated IFN-γ production were observed in clone 7-immunized mice. Clone 7 was named "KVAC103" and was used for the skin toxicity test and full-genome analysis. KVAC103-inoculated rabbits showed reduced skin lesions compared to those inoculated with the Lister strain, Lancy-Vaxina. A whole genome analysis of KVAC103 revealed two major deleted regions that might contribute to the reduced virulence of KVAC103 compared to the Lister strain. Phylogenetic inference supported the close relationship with the Lister strain. Collectively, our data demonstrate that KVAC103 holds promise for use as a third-generation smallpox vaccine strain due to its enhanced safety and efficacy.

Development of functional epitope and neutralizing antibody of variola virus

Functional epitopes and neutralizing antibodies of vaccinia virus

Designing a smallpox B-cell and T-cell multi-epitope subunit vaccine using a comprehensive immunoinformatics approach

Treatment and Vaccination for Smallpox and Monkeypox

Biology of Variola Virus

Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine

Protective Human Anti-Poxvirus Monoclonal Antibodies Are Generated from Rare Memory B Cells Isolated by Multicolor Antigen Tetramers

Therapeutic Strategies for Human Poxvirus Infections: Monkeypox (mpox), Smallpox, Molluscipox, and Orf

Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches

The Current State and Progress of Mpox Vaccine Research

Development of an attenuated smallpox vaccine candidate: The KVAC103 strain

Host Range, Growth Property, and Virulence of the Smallpox Vaccine: Vaccinia Virus Tian Tan Strain

Potential Threat of Human Pathogenic Orthopoxviruses to Public Health and Control Strategies.

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

Epidemiological Analysis of Varicella in China and Advance in Immunity Prevention for Varicella Vaccine

Genomic Sequence And Virulence Of Clonal Isolates Of Vaccinia Virus Tiantan, The Chinese Smallpox Vaccine Strain

Progress in Clinical Research of Varicella Vaccines

[Genomic structure of varicella-zoster virus and its vaccine application status]

Development of Smallpox Antibody Testing and Surveillance Following Smallpox Vaccination in the Republic of Korea

Vaccinia virus tiantan strain is inefficient in eliciting cross-reactive immunity against the emerging monkeypox virus strain

Research Progress and Challenges in Vaccine Development Against Classical Swine Fever Virus